Showing posts with label Car t cell therapy Market Report. Show all posts
Showing posts with label Car t cell therapy Market Report. Show all posts

Monday, 5 April 2021

Electric Traction Motor Market Incredible Possibilities, Growth Analysis And Forecast To 2027

 The global electric traction motors market is anticipated to reach USD 31.5 billion by 2026 according to a new study published by Polaris Market Research.

 

Electric traction motors are the most common means for powering locomotive engines in the currently developed railway industry, but with the growing need for sustainable use of energy, the advent of the application of traction motors has added to an efficient use and distribution of energy in the industry. Electric traction motors are widely being used across several geographies particularly for the routes with dense traffic such as the suburban and urban railways or the long distance high speed lines that require electric traction to obtain the speeds required for inter-city travel. This equipment cut down energy losses to an estimated figure of approximately 15% with an assumption of energy at wheel of 100%. With application of new traction chain, energy inputs in locomotives decrease from 167% to around 143% under the similar assumptions. Application of electric traction motors in railway engines result in cut in energy loss wherein for transformers it reduces from 10.3% to 7%, converters from 18.1% to 4.7%, gearbox and motor from 18.2% to 12.2%, vehicle parking 7.6% 8.4% (higher percentage value due to reduced total loses) and power house & auxiliary systems from 12.4% to 9.9%.

 

Get Sample : https://www.polarismarketresearch.com/industry-analysis/electric-traction-motor-market/request-for-sample

 

DC traction motors were conventionally the moist used types on both electric and diesel-electric rolling stock, however the contemporary power electronics has enabled application of AC motors. For most of the new engines built today, AC motor is the most preferred type. AC motors have certain advantages such as its simple for manufacturing as this type requires no mechanical contracts for its functioning, lighter compared to DC motors for equivalent amount of power. Use of modern and advanced electronics allows the AC units to be controlled efficiently to improve traction and adhesion. It can be controlled with microprocessors to a specific degree which also helps in regenerating current down to almost a stop whereas DC regeneration fades quickly at low speeds. Moreover, AC motors are more robust and easier to maintain than DC motors. These products are also being used in electric vehicles, conveyors and industrial machinery in the present industry space. It automobiles too, more than DC the AC motors has the larger share of application.

  

Asia Pacific region is expected to be the fastest growing market for production of electric traction motors over the forecast period from 2018 to 2026. Development of the industrial equipment manufacturing industry in India, Japan and especially China with its massive domestic demand figures is the major driving factors for the regions fast increasing consumption of these products in the railway engine manufacturing industry.

 

The worldwide demand for freight and passenger rail equipment including its infrastructure and related services in 2016 was estimated USD 214 billion in 2016. The increasing network of railways globally is a major factor to contribute to the increasing demand of rail equipment including the electric traction motors.

 

Get Offer : https://www.polarismarketresearch.com/industry-analysis/electric-traction-motor-market/request-for-discount-pricing

 

The Western Europe has been dominating the global market for production of these products and also in terms of exports, followed by the Asia Pacific and the U.S. in the third position. But the increasing subways and urban light railway systems and yearly increasing investment in intercity high-speed rail lines in Asia Pacific countries due to need from its growing population, manufacturing industry of these products in the region is likely to witness the fastest growth in the next eight years. Some of the leading industry participants include Weg Sa, Toshiba, Skoda Electric, NIDE, General Electric (GE), CG Power, Bosch, Siemen, Traktionssysteme Austria, Alsto and Crr.

 

Car t cell therapy Market Incredible Possibilities, Growth Analysis And Forecast To 2027

The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market. The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research


This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.   

 

Request for a sample of this research Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

 

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

 

 

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

 

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

 

Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying

 

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

 

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

 

Read More : https://www.medgadget.com/2020/02/car-t-cell-therapy-market-worth-8-92-billion-by-2026-cagr-34-5-polaris-market-research.html